Selexis SA to Present at Biotech Showcase 2012

Share Article

Dr. Igor Fisch to Present in the Private Company Track

Igor Fisch, PhD, Selexis CEO

Igor Fisch, PhD, Selexis CEO

Using Selexis’ platform from discovery through manufacturing helps improve chances of clinical success while reducing development timelines and costs

Selexis SA announced today the Company’s president and CEO, Igor Fisch, Ph.D., will present at the Biotech Showcase 2012 Conference held in conjunction with the annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Dr. Fisch will present, “Translating Drug Discovery into Clinical Success: A Growth Investment” to prospective investors and corporate partners on Monday, January 9 at 11:00 AM in the Stockton Room at the Park 55 Wyndham. The presentation will cover existing commercial offerings, the expansion of the SUREtechnology Platform™ and new market opportunities in drug discovery, next generation biologics and difficult to express proteins.

“Biotech Showcase is an ideal opportunity for us to highlight our innovations and our applications of the SUREtechnology Platform™ supporting the biopharmaceutical industry’s drug discovery efforts,” said Dr. Fisch. “Using Selexis’ platform from discovery through manufacturing helps improve chances of clinical success while reducing development timelines and costs .”

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.
For more information, visit http://www.selexis.com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robert Meister
Selexis SA
(602) 953-1716
Email >
Visit website